Reviva Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 260.00 thousand shares for the 1-month period ending 2023-08-31, per its 10-Q filed 2023-11-14.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2023-11-14
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-03-31 was 0.00 shares.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 5.00K shares.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-06-30 was 0.00 shares.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-03-31 was 0.00 shares.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 127.43K shares.
- Reviva Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|---|
| 2023-08-31 | 260.00K shares 10-Q · filed 2023-11-14 | |||||
| 2023-04-25 | 1.30M shares 10-Q · filed 2023-11-14 | |||||
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-15 | |||||
| 2022-09-30 | 5.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 5.00K shares derived: sum of 2 quarters · filed 2022-11-14 | 5.00K shares 10-Q · filed 2022-11-14 | 51.20K shares derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 0.00 shares 10-Q · filed 2022-08-15 | 46.20K shares derived: sum of 3 quarters · filed 2023-05-15 | 46.20K shares derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2022-03-31 | 0.00 shares 10-Q · filed 2023-05-15 | 46.20K shares derived: sum of 2 quarters · filed 2023-05-15 | 46.20K shares derived: sum of 3 quarters · filed 2023-05-15 | |||
| 2021-12-31 | 46.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | 46.20K shares derived: sum of 2 quarters · filed 2022-03-15 | 127.43K shares 10-K · filed 2022-03-15 | |||
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 81.23K shares 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | 81.23K shares 10-Q · filed 2021-08-16 | |||||
| 2020-12-31 | 0.00 shares 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |